NovoCure/$NVCR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About NovoCure
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
Ticker
$NVCR
Sector
Primary listing
Industry
Health Care Equipment & Supplies
Headquarters
Baar, Switzerland
Employees
1,488
ISIN
JE00BYSS4X48
Website
NovoCure Metrics
BasicAdvanced
$1.9B
-
-$1.51
0.65
-
Price and volume
Market cap
$1.9B
Beta
0.65
52-week high
$34.13
52-week low
$14.17
Average daily volume
1.4M
Financial strength
Current ratio
1.465
Quick ratio
1.409
Long term debt to equity
38.06
Total debt to equity
192.489
Interest coverage (TTM)
-15.84%
Profitability
EBITDA (TTM)
-153.508
Gross margin (TTM)
77.32%
Net profit margin (TTM)
-26.41%
Operating margin (TTM)
-26.36%
Effective tax rate (TTM)
-26.48%
Revenue per employee (TTM)
$420,000
Management effectiveness
Return on assets (TTM)
-8.64%
Return on equity (TTM)
-45.52%
Valuation
Price to revenue (TTM)
2.934
Price to book
5.17
Price to tangible book (TTM)
5.17
Price to free cash flow (TTM)
-25.287
Free cash flow yield (TTM)
-3.95%
Free cash flow per share (TTM)
-66.44%
Growth
Revenue change (TTM)
18.27%
Earnings per share change (TTM)
-16.51%
3-year revenue growth (CAGR)
4.95%
10-year revenue growth (CAGR)
42.90%
3-year earnings per share growth (CAGR)
38.67%
10-year earnings per share growth (CAGR)
-13.86%
What the Analysts think about NovoCure
Analyst ratings (Buy, Hold, Sell) for NovoCure stock.
Bulls say / Bears say
Novocure's Optune Lua received FDA approval for the treatment of metastatic non-small cell lung cancer, expanding the company's market reach and potential revenue streams. (novocure.com)
The Phase 3 PANOVA-3 trial met its primary endpoint, demonstrating a statistically significant improvement in overall survival for patients with unresectable, locally advanced pancreatic cancer, potentially leading to new treatment indications. (novocure.com)
Novocure reported a 19% year-over-year increase in net revenues for 2024, indicating strong financial performance and growth potential. (novocure.com)
Novocure reported a net loss of $65.9 million in Q4 2024, indicating ongoing profitability challenges. (novocure.com)
The company's gross margin is expected to be impacted by product enhancements and the launch of Optune Lua in metastatic non-small cell lung cancer, potentially affecting profitability. (novocure.com)
Novocure anticipates meaningful revenue contribution from the lung cancer indication starting in 2026, suggesting a delay in realizing returns from recent approvals. (novocure.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2025.
NovoCure Financial Performance
Revenues and expenses
NovoCure Earnings Performance
Company profitability
NovoCure News
AllArticlesVideos
NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial
Benzinga·3 weeks ago
Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
Business Wire·3 weeks ago
Results From the Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for NovoCure stock?
NovoCure (NVCR) has a market cap of $1.9B as of June 20, 2025.
What is the P/E ratio for NovoCure stock?
The price to earnings (P/E) ratio for NovoCure (NVCR) stock is 0 as of June 20, 2025.
Does NovoCure stock pay dividends?
No, NovoCure (NVCR) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next NovoCure dividend payment date?
NovoCure (NVCR) stock does not pay dividends to its shareholders.
What is the beta indicator for NovoCure?
NovoCure (NVCR) has a beta rating of 0.65. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.